INO (Inovio Pharmaceuticals, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by INO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-21 | PETER KIES | CFO | MIXED | — | — |
| 2026-05-21 | WENDY L YARNO | Director | A | — | — |
| 2026-05-21 | SIMON X BENITO | Director | A | — | — |
| 2026-05-21 | Lota S. Zoth | Director | A | — | — |
| 2026-05-21 | ROGER D DANSEY | Director | A | — | — |
| 2026-05-21 | Michael John Sumner | Chief Medical Officer | MIXED | — | — |
| 2026-05-21 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | — | — |
| 2026-05-21 | Laurent Humeau | Chief Scientific Officer | MIXED | — | — |
| 2026-05-21 | Jay Shepard | Director | A | — | — |
| 2026-05-21 | Ann Calby Miller | Director | A | — | — |
| 2026-05-21 | David B. Weiner | Director | A | — | — |
| 2026-05-18 | Laurent Humeau | Chief Scientific Officer | MIXED | — | — |
| 2026-05-18 | PETER KIES | CFO | MIXED | — | — |
| 2026-05-18 | Michael John Sumner | Chief Medical Officer | MIXED | — | — |
| 2026-05-18 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | — | — |
| 2026-04-01 | Michael John Sumner | Chief Medical Officer | MIXED | — | — |
| 2026-03-05 | Michael John Sumner | Chief Medical Officer | A | — | — |
| 2026-03-05 | Laurent Humeau | Chief Scientific Officer | A | — | — |
| 2026-03-05 | Jacqueline Elizabeth Shea | Chief Executive Officer | A | — | — |
| 2026-03-05 | PETER KIES | CFO | A | — | — |
| 2026-02-27 | Laurent Humeau | Chief Scientific Officer | MIXED | — | — |
| 2026-02-27 | PETER KIES | CFO | MIXED | — | — |
| 2026-02-27 | David B. Weiner | Director | M | — | — |
| 2026-02-27 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | — | — |
| 2026-02-27 | Michael John Sumner | Chief Medical Officer | MIXED | — | — |
| 2025-07-01 | Michael John Sumner | Chief Medical Officer | M | — | — |
| 2025-05-21 | WENDY L YARNO | Director | M | — | — |
| 2025-05-21 | Lota S. Zoth | Director | M | — | — |
| 2025-05-21 | David B. Weiner | Director | M | — | — |
| 2025-05-21 | Jacqueline Elizabeth Shea | Chief Executive Officer | A | — | — |
| 2025-05-21 | SIMON X BENITO | Director | M | — | — |
| 2025-05-21 | Laurent Humeau | Chief Scientific Officer | A | — | — |
| 2025-05-21 | Jay Shepard | Director | M | — | — |
| 2025-05-21 | Michael John Sumner | Chief Medical Officer | A | — | — |
| 2025-05-21 | Ann Calby Miller | Director | M | — | — |
| 2025-05-21 | PETER KIES | CFO | A | — | — |
| 2025-05-21 | ROGER D DANSEY | Director | M | — | — |
| 2025-05-16 | Michael John Sumner | Chief Medical Officer | MIXED | — | — |
| 2025-05-16 | PETER KIES | CFO | MIXED | — | — |
| 2025-05-16 | Laurent Humeau | Chief Scientific Officer | MIXED | — | — |
| 2025-05-16 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | — | — |
| 2025-05-12 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | — | — |
| 2025-02-28 | David B. Weiner | Director | M | — | — |
| 2025-02-28 | Laurent Humeau | Chief Scientific Officer | MIXED | — | — |
| 2025-02-28 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | — | — |
| 2025-02-28 | Michael John Sumner | Chief Medical Officer | M | — | — |
| 2025-02-28 | PETER KIES | CFO | MIXED | — | — |
| 2024-12-18 | Michael John Sumner | Chief Medical Officer | A | — | — |
| 2024-07-01 | Michael John Sumner | Chief Medical Officer | M | — | — |
| 2024-05-22 | SIMON X BENITO | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 124,654 | — |
| — | Chief Executive Officer | 123,327 | — |
| — | Director | 87,592 | — |
| — | 10%+ Owner | 81,661 | — |
| — | Chief Scientific Officer | 48,986 | — |
| — | Chief Medical Officer | 44,731 | — |
| — | CFO | 43,229 | — |
| — | Director | 19,407 | — |
| — | Sr. VP Business Development | 15,127 | — |
| — | Director | 12,191 | — |
| — | Director | 10,512 | — |
| — | Director | 9,877 | — |
| — | Director | 9,209 | — |
| — | Chief Operating Officer | 9,059 | — |
| — | Director | 8,916 | — |
| — | Director | 8,834 | — |
| — | Director | 8,726 | — |
| — | Chief Medical Officer | 8,389 | — |
| — | Director | 6,300 | — |
| — | Director | 1,889 | — |
| — | Director | 417 | — |
| — | Director | 341 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INO quote page; the site-wide leaderboard is on the insider transactions hub.